Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Completes $230M Public Offering

NEW YORK (GenomeWeb) – Intrexon today said that it completed a public offering that raised $230 million in gross proceeds. 

The firm sold 5,609,756 shares of its common stock at $41 per share, which included 731,707 shares purchased by the offering's underwriters under an option granted to them by Intrexon. 

JMP Securities was the sole book-running manager while Stifel was the lead manager on the offering. Griffin Securities and Wunderlich Securities were the co-managers. 

Proceeds will be used for general corporate purposes and strategic acquisitions or investments, the Germantown, Maryland-based synthetic biology firm said when it originally announced the offering last week.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.